Table 2. Relative frequency of CKD evolution per stage of users and non-users of omeprazole followed-up at the nephrology ambulatory clinic of the Municipal Polyclinic of Divinópolis-MG, Brazil, 2016–2017 (n = 199).
| CKD evolution | General (n = 199) | Non-omeprazole users (n = 114) | Omeprazole users (n = 85) | p-value |
|---|---|---|---|---|
| Total | 36.2% | 10.5% | 70.6% | < 0.0001* |
| Stage 2 → Stage 3a | 2.4% | 0.0% | 5.5% | |
| Stage 3a → Stage 3b | 16.9% | 7.6% | 29.5% | |
| Stage 3b → Stage 4 | 12.9% | 2.9% | 26.4% | |
| Stage 4 → Stage 5 ND | 3.9% | 0.0% | 9.2% | |
| Stage 5 ND → Stage 5 D | 0.0% | 0.0% | 0.0% |
* Two-tailed Pearson chi-square test; CKD: Chronic kidney disease; ND: Non-dialytic.; D: Dialytic.